fda aod9604 approval status AOD-9604 Clinical Trial Results & (2026) AOD 9604 Dosage: What It

While AOD 9604 offers a safer and potentially cost-effective approach with added joint health benefits, Semaglutide stands out as the most effective option for significant weight loss, supported by robust clinical research

Treatment reduces circulating markers of metabolic dysfunction and inflammation, creating a more favorable metabolic environment that supports insulin sensitivity and glucose regulation

In the Phase 2b trial (2007, n=536) AOD-9604 showed weight reduction only 0.3 kg greater than placebo after 24 weeks

However, it is essential to distinguish between the known biological roles of each ingredient and the unproven claim that injecting them together produces clinically meaningful fat loss